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The molecular mechanisms whereby the CD45
tyrosine phosphatase (PTPase) regulates T
cell receptor (TCR) signaling responses remain
to be elucidated. To investigate this question,
we have reconstituted CD45 (encoded by
Ptprc)-deficient mice, which display severe
defects in thymic development, with five differ-
ent expression levels of transgenic CD45RO,
or with mutant PTPase null or PTPase-low
CD45R0. Whereas CD45 PTPase activity was
absolutely required for the reconstitution of
thymic development, only 3% of wild-type
CD45 activity restored T cell numbers and nor-
mal cytotoxic T cell responses. Lowering the
CD45 expression increased CD4 lineage com-
mitment. Peripheral T cells with very low activity
of CD45 phosphatase displayed reduced TCR
signaling, whereas intermediate activity caused
hyperactivation of CD4+ and CD8+ T cells. These
results are explained by a rheostat mechanism
whereby CD45 differentially regulates the nega-
tively acting pTyr-505 and positively acting
pTyr-394 p56lck tyrosine kinase phosphorylation
sites. We propose that high wild-type CD45
expression is necessary to dephosphorylate
p56lck pTyr-394, suppressing CD4 T+ cell line-
age commitment and hyperactivity.
INTRODUCTION
The transmembrane and heavily glycosylated CD45
tyrosine phosphatase (PTPase) has attracted attention
because of its high expression on the surface of T and
B lymphocytes (Alexander, 2000; Hermiston et al., 2003;
Holmes, 2006). Why does an enzyme need to be so abun-
dant at the T cell surface? No physiologically relevant
exogenous CD45 ligands have yet been identified,
although various lectins have been suggested (van VlietImet al., 2006). Considerable attention has been given to
the alternative splicing of CD45 in T cells, generating up
to eight different CD45 isoforms, differing only in their
ectodomains (Beverley et al., 1992). These isoforms
appear to differentially associate in cis with the CD4 and
CD8 coreceptors, thereby providing a feasible mecha-
nism whereby the CD45 phosphatase can act on CD4
and CD8-associated p56lck tyrosine kinase, which is crit-
ical for the initiation of T cell receptor (TCR)-mediated sig-
nals (Dornan et al., 2002; Leitenberg et al., 1996). Further-
more, CD45 isoforms can differentially homodimerize,
particularly at higher expression, possibly leading to inhi-
bition of the phosphatase activity, a finding with relevance
to autoimmunity (Majeti et al., 1998, 2000; Xu and Weiss,
2002). A further possible isoform-dependent mechanism
involves the differential targeting of CD45 to p56lck in lipid
rafts (Irles et al., 2003). Several reports have also high-
lighted the importance of CD45 expression in its differen-
tial regulation of TCR signaling amplitude. For example, it
is well established that CD45 expression increases during
T cell development, becoming 2-fold higher in the periph-
ery than in the thymus (McNeill et al., 2004). This corre-
lates with a change in the sensitivity of TCR signaling re-
sponses from high in the thymus to much lower in the
periphery (Grossman and Singer, 1996; Sebzda et al.,
1996). The threshold of TCR engagement required for
activation is reduced even further in Ptprc+/ (encoding
CD45) mice thymocytes in which CD45 PTPase activity
is lower and positive selection is amplified (Wallace
et al., 1997). The varying concentration of CD45 in specific
subcellular localizations has also received attention in the
context of signaling studies on the immune synapse and
on microclusters (Campi et al., 2005; Douglass and
Vale, 2005; Varma et al., 2006; Yokosuka et al., 2005).
Such findings have stimulated the focus of our present
study, which is on the differential expression of CD45
and the way in which the consequent titration of its phos-
phatase activity is critical in dictating TCR signaling
responses.
The most important substrate for CD45 in T cells is the
p56lck tyrosine kinase (Ostergaard et al., 1989), p59fyn
also being a substrate (Mustelin et al., 1992). CD45 is
the only known phosphatase that dephosphorylates themunity 27, 425–437, September 2007 ª2007 Elsevier Inc. 425
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CD45 Regulation of TCR ResponsesFigure 1. Effects of Altered PTPase Activity on T Cell Differentiation in Mutant CD45RO-PTPase Mice
(A) Cell-surface expression of CD45 on thymocytes from wild-type (gray histogram), Ptprc/ (black histogram), and CD45RO-C817S, CD45RO-
V821S, and CD45RO9 as unfilled histograms from left to right, respectively.
(B) Thymic CD45 expression (diamond) and membrane PTPase activity (bar) presented as average percentage of wild-type (mean ± SEM, minimum
of 5 mice for each group).
(C) Flow cytometry of DN thymocytes (gated CD4CD8 cells) showing CD44 and CD25 expression. Numbers in quadrants indicate the frequency of
DN2 (CD44+CD25+) and DN3 (CD44CD25+) thymocytes.
(D) Flow cytometry analysis of CD4 andCD8 expression on thymocytes with CD4+CD8+, CD4+SP, and CD8+SP thymocyte populations highlighted by
gating. Numbers indicate the frequency of cells in each gated population.426 Immunity 27, 425–437, September 2007 ª2007 Elsevier Inc.
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CD45 Regulation of TCR Responsesnegative regulatory p56lck pTyr-505 site, counteracting an
intramolecular association that downregulates kinase
function (Veillette et al., 1992). In addition, CD45 dephos-
phorylates the activatory autophosphorylation p56lck
pTyr-394 site, thereby suppressing kinase activity (Doro
and Ashwell, 1999; Zhao et al., 2004), although in this
case other phosphatases are thought to act at this site,
such as PEP (Hasegawa et al., 2004) and SHP-1 (Chiang
and Sefton, 2001). In Ptprc/ mice, the threshold for
TCR signaling becomes very high, in a way that cannot
be compensated for by PEP or SHP-1, leading to severe
thymic developmental defects and the accumulation of
only about 5% the normal numbers of peripheral T cells,
rendering studies on mature murine Ptprc/ T cells prob-
lematic (Byth et al., 1996; Kishihara et al., 1993; Mee et al.,
1999). To circumvent this problem, we have in the present
work reconstituted Ptprc/ mice with a broad range of
expression of a single isoform, CD45RO, in both wild-
type and mutant forms. Our results show that whereas
CD45 function is absolutely dependent on its phospha-
tase activity in the whole animal context, only 3% of nor-
mal phosphatase functionality is sufficient to reconstitute
thymic development, whereas levels in the range of 10%–
20% are required for full peripheral function. We present
data suggesting that the main reason for high CD45
expression in the wild-type context is to suppress the
hyperactivation of peripheral T cells by dephosphorylating
p56lck pTyr-394.
RESULTS
Generation of TransgenicMice ExpressingMutant
CD45RO Isoforms with Altered PTPase Activity
CD45 has two phosphatase homology domains located in
the cytoplasmic tail, with only domain I being catalytically
active, whereas domain II is thought to have a regulatory
role. Point mutations in either of these domains can result
in a reduction in PTPase activity (Johnson et al., 1992). We
selected two of these previously published point muta-
tions in domain I: C817S, which has been shown to ablate
PTPase activity, and V821S, which has been shown to
reduce wild-type PTPase activity to an estimated 25%,
an amount we hypothesized might be sufficient to
reconstitute thymic development in Ptprc/mice. By us-
ing rCD45 cytoplasmic tail protein, we found that both
these mutations significantly reduced PTPase activity
(t test, p < 0.01; Figure S1 in the Supplemental Data avail-
able online), whereas the so-called wedge mutant
E613R was found to have normal PTPase activity (t test,
p = 0.18).
We have previously described transgenic mouse lines
expressing varying amounts of CD45RO under the control
of the vav promoter (Ogilvy et al., 2003). To complementImthese, CD45RO-V821S and CD45RO-C817S transgenic
lines were generated to give expression of the individual
CD45RO isoform with low or null PTPase activity. To eval-
uate expression of the transgene, thymocytes were ana-
lyzed for surface CD45 expression by flow cytometry
(Figure 1A): CD45RO-C817S thymocytes were found to
express CD45 protein at 19.0% ± 1.5% and CD45RO-
V821S at 24.7% ± 0.5% of total CD45 wild-type amounts
(compared to a value including all isoforms). The
CD45RO9 transgenic line, described previously (Ogilvy
et al., 2003), provided a relevant control expressing the
CD45RO isoform at a closely matched (29.8% ± 2.5%)
amount to CD45RO-V821S. This allowed the effect of
reduced CD45 PTPase activity to be compared directly
between these two transgenic lines.
To determine the CD45PTPase activity in primary trans-
genic cells in vivo, we prepared membrane fractions with-
out detergent to prevent disruption of physiologically
relevant associations and measured PTPase activities by
using a phosphopeptide substrate. PTPase activity in
Ptprc/ thymic membrane samples was reduced to
3.6% of the wild-type amount, showing that nearly all
the PTPase measured by the assay was attributable to
CD45 (Figure 1B). As expected, CD45 PTPase activity in
CD45RO-C817S membranes was ablated. CD45RO-
V821S valueswere 17%of control CD45RO9membranes,
and this reduction, in combination with the lower protein
expression compared with C57BL/6, gave this transgenic
line an equivalent CD45 PTPase function of just 3.0% of
wild-type.
Phenotypic Analysis of CD45RO-V821S
and CD45RO-C817S Transgenic Mice
It is possible that the CD45 ectodomain has a function that
is independent of CD45 PTPase activity. The generation of
the PTPase-dead CD45RO-C817S line enabled us to
address this question. For clarity, phenotypic data are
presented below as two types of comparison: either com-
paring the CD45mutant PTPase CD45RO-V821S line with
its CD45RO9 expression-matched control, in order to
assess the effect of reducing CD45 PTPase activity by
80%, or comparing mice varying in unmutated transgenic
CD45RO expression. Comparison of CD45RO-C817S
and Ptprc/ mice revealed equivalent blocks in thymic
development at the DN and DP stages (Figures 1C and
1D), resulting in greatly reduced thymic CD4SP and
CD8SP cell numbers (Figure 1D) and few mature periph-
eral T cells (Figure 1E; Table S1). These results show
that the CD45RO ectodomain is unable to function
independently of CD45 PTPase activity during T cell
development.
However, expression of PTPase-low CD45RO-V821S
restored thymic differentiation (Figures 1C and 1D) and(E) Flow cytometry analysis of CD4 and CD8 expression on peripheral lymph node cells with CD4+ T cells and CD8+ T cells highlighted by gating.
Numbers indicate the frequency of cells in each gated population.
(F) Flow cytometry analysis of CD44 and CD62L expression on gated CD4+ and CD8+ T cells from peripheral lymph node. Numbers indicate the
frequency of cells in each quadrant. All flow cytometric data are representative of four independent experiments.munity 27, 425–437, September 2007 ª2007 Elsevier Inc. 427
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CD45 Regulation of TCR Responsesa peripheral T cell repertoire (Figure 1E) in which total T cell
numbers were comparable with age-matched wild-type
mice (Table S1). The absolute numbers of CD4SP and
CD8SP thymocytes in CD45RO9 mice were significantly
higher than wild-type (t test, p < 0.01), by 82% and 53%,
respectively, and this was reflected in the periphery by
a 42% increase (t test, p < 0.01) in CD4+ T cell, but not
CD8+ T cell, numbers. CD45RO-V821S mice also showed
a 78% increase (t test, p < 0.01) in the number of CD4SP
thymocytes, but this was not reflected in the periphery,
where CD4+ T cells numbers were comparable to wild-
type. CD8SP numbers in CD45RO-V821S mice were not
altered, but peripheral CD8+ T cells showed a 38%
decrease in absolute numbers (t test, p < 0.01). Interest-
ingly, an increased proportion of peripheral CD8+ T cells
from both CD45RO9 and CD45RO-V821S mice fell into
the CD44hi population (Figure 1F), the majority of these
cells also being CD62Lhi, indicative of a memory-type
phenotype.
Therefore, only 3% of the normal amount of CD45
PTPase is sufficient to reconstitute Ptprc/ mice with
normal numbers of mature T cells, albeit biased toward
CD4+ T cell lineage commitment and with changes within
the peripheral CD8+ T cell population.
Reduction in CD45 Expression Enhances CD4
Lineage Commitment
To further investigate the impact of CD45 on T cell devel-
opment, we examined thymocytes from wild-type,
Ptprc+/, Ptprc/, and five independent CD45RO trans-
genic lines. The relative thymic CD45 expression on these
lines varied from 1.3% ± 0.5% (CD45RO5) to 59.9% ±
2.4% (Ptprc+/) of wild-type (Figure 2A; complete data
are in Table S1). Measurement of thymic membrane
CD45 PTPase activities revealed a linear relationship
(R2 = 0.969) between CD45 expression and activity
(Figure 2B), and comparable results were found in periph-
eral CD4+ and CD8+ T cell membranes with no difference
in total CD45 expression or PTPase activity noted be-
tween these two T cell subsets (Figures S2 and S3). As
the expression, and so CD45 PTPase activity, decreases,
a bias toward the positive selection of CD4+ T cells was
apparent (Figure 2C); this resulted in a higher number of
CD4+ T cells in the periphery (Figure 2D). Only when the
CD45 expression fell below 2% (as in the CD45RO5 line)
was there a marked failure in the positive selection of
both CD4+ and CD8+ T cells (Figures 2C and 2D). As noted
for the CD45RO-V821S mice, the CD8+ population also
showed alterations in the frequency of CD44hi CD62Lhi
cells (Figure 2E), with the proportion of CD8+ T cells in
this population increasing as CD45 expression was re-
duced. In the following studies, CD44lo CD8+ T cells
from all mice were either gated or purified to ensure that
analysis was carried out on comparable populations.
Overall, these results show that wild-type CD45 expres-
sion restrains commitment to the CD4+ T cell lineage,
a restraint much reduced when CD45 PTPase activity
is lowered to intermediate amounts (10%–60% of
wild-type).428 Immunity 27, 425–437, September 2007 ª2007 Elsevier IncReduced CD45 Expression Results in Altered
p56lck Phosphorylation and Increased Thymic
Signaling
Because the CD45-mediated restraint on the positive
selection of CD4+ T cells was reduced at lower CD45
expression, we investigated the signaling events that
might explain this finding. Phosphorylation of activatory
and inhibitory p56lck Tyr residues were assessed by
FACS analysis via commercially available antibodies
against active src family kinase and pTyr-505, respec-
tively. Similar results were achieved with specific anti-
Lck pTyr-394 sera (Holdorf et al., 2002; data not shown).
In gated DP thymocytes, both p56lck pTyr-505 and pTyr-
394 amounts increased as the expression of CD45 was
reduced (Figure 3A). The increase in the phosphorylation
of the two pTyr residues was comparable at intermediate
CD45 expression, but in CD45RO5 and Ptprc/ cells, the
phosphorylation of pTyr-505 became very high. Stimula-
tion with CD3 mAb made little obvious difference to the
amount of pTyr-505 (data not shown). To demonstrate
directly increased signaling capacity in cells with interme-
diate CD45 expression, we measured CD3-stimulated
signals in DP thymocytes, showing that the proportion of
DP thymocytes with enhanced staining of phospho-PKB
(Figure 3B) was increased above wild-type at intermediate
CD45 levels. Of particular importance was the finding that
signaling via phospho-ERK was also markedly increased
(Figure 3C) because a clear correlation between CD4 line-
age commitment and activation of the Ras-MAPK path-
way has previously been established (Sharp and Hedrick,
1999; Sharp et al., 1997; Sugawara et al., 1998). The kinet-
ics of ERK and PKB activation were found to be similar in
wild-type and CD45RO transgenic mice irrespective of the
CD45 expression (data not shown). In the lowest express-
ing CD45RO5 line, in which the amounts of p56lck pTyr-
505 were very high, both phospho-PKB and phospho-
Erk signals were reduced compared to wild-type, whereas
in Ptprc/ thymocytes, no CD3-stimulated signaling re-
sponses were noted. Overall these results show that in
the thymus, the sensitivity of cells to TCR stimulation in-
creases as CD45 expression decreases, associated with
increased pTyr-394 and amplified signals, until in
CD45RO5 mice the inhibitory effects of pTyr-505 hyper-
phosphorylation become dominant, and then finally in
Ptprc/ cells, p56lck becomes dysfunctional (Stone
et al., 1997).
Amplified TCR Signals in Peripheral T Cells
with Intermediate CD45 PTPase Activity
Wild-type thymocytes generally display lower TCR signal-
ing thresholds compared to mature peripheral T cells
(Grossman and Singer, 1996; Sebzda et al., 1996). Given
our finding that the sensitivity of thymocytes to TCR stim-
ulation was affected by decreased CD45 expression, it
was therefore of interest to determine whether compara-
ble results were demonstrable in mature CD4 and CD8 T
cells. The reconstitution of mature T cell repertoires on
a Ptprc/ background in a wide range of CD45RO, as
well as mutant CD45RO-V821S, transgenic lines provided.
Immunity
CD45 Regulation of TCR ResponsesFigure 2. T Cell Differentiation in Transgenic Mice Varying in CD45RO Expression
(A) Flow cytometry of cell-surface expression of CD45 on thymocytes from wild-type (gray histogram), Ptprc/ (black histogram), and CD45RO5,
CD45RO4, CD45RO10, CD45RO9, CD45RO3, and Ptprc+/ as unfilled histograms from left to right, respectively.
(B) Thymic CD45 expression and membrane PTPase activity from the transgenic CD45RO lines. Each data point represents an individual mouse and
the linear regression analysis is shown.
(C and D) Absolute cell numbers of CD4+ (gray) and CD8+ (striped) thymocytes (C) and CD4+ (gray) and CD8+ (striped) T cells in the spleen (D)
determined by flow cytometry. Data are mean ± SEM with a minimum of 3 mice per line; full data can be found in Table S1.
(E) Flow cytometry analysis of CD44 and CD62L expression on gated CD4+ and CD8+ T cells from peripheral lymph node. Numbers indicate the
frequency of cells in each quadrant. All flow cytometric data are representative of four independent experiments.a unique set of reagents for addressing this question. A
striking increase in CD3-stimulated splenic CD4+ T cell
proliferation was observed with decreasing CD45 expres-
sion, up to a 5-fold increase when expression was
reduced to 30%–40% of wild-type, and even CD45RO-
V821S T cells displayed proliferation comparable with
wild-type (Figure 4A). Costimulation with CD28 enabled
CD4+ CD45RO-V821S cells to proliferate 3-fold higher
than wild-type (Figure 4B). An increase in CD3-stimulated
CD44lo CD8+ T cell proliferation (Figure 4C) was also notedImmat intermediate CD45 expression, but in this case
CD45RO-V821S proliferation was reduced compared
with wild-type. CD28 costimulation (Figure 4D) was unable
to enhance proliferation of CD8+ T cells from the lower
CD45-expressing lines.
The proliferation data suggest that at intermediate CD45
expression (10%–60% of wild-type), peripheral T cells are
more responsive to TCR stimulation. We explored this
question further by measuring TCR-induced signals. Flow
cytometric analysis revealed a dose-response curve inunity 27, 425–437, September 2007 ª2007 Elsevier Inc. 429
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CD45 Regulation of TCR ResponsesFigure 3. CD45RO Transgenic Thymocytes Display Enhanced TCR Signaling
(A) Flow cytometry of p56lck pTyr-505 and pTyr-394 staining (unfilled histogram) in gated DP thymocytes compared with wild-type (dark gray histo-
gram) and isotype control (light gray histogram). Numbers indicate the n-fold increase in phosphorylation compared with wild-type. Data are repre-
sentative of three independent experiments.
(B) Number of DP thymocytes becoming phospho-PKB +ve after 3 min TCR stimulation with various concentrations of CD3 antibody (2C11: white,
none; black, 2 mg/ml; gray, 10 mg/ml; striped, 50 mg/ml). Phosphorylation was measured by flow cytometry and is representative of at least three
independent experiments.
(C) Number of DP thymocytes becoming phospho-PKB positive after 3 min TCR stimulation with various concentrations of CD3 antibody (2C11:
white, none; black, 2 mg/ml; gray, 10 mg/ml; striped, 50 mg/ml). Phosphorylation was measured by flow cytometry and is representative of at least
three independent experiments.which theproportion of bothCD4+andCD44loCD8+Tcells
with high amounts of phospho-ERK (Figure 4E) and phos-
pho-PKB staining (Figure S4D)wasmuch increased above
wild-type at intermediate CD45 expression, but the pro-
portion was reduced in CD45RO-V821S and ablated in
Ptprc/ cells. Furthermore, TCR-induced calcium release
and upregulation of the activation markers CD25 and
CD69 by CD4+ T cells followed the same pattern
(Figure S4). Together, these data suggest that reducing
amounts of CD45 in peripheral T cells initially enhance re-
sponses, whereas at low amounts of CD45 expression,
TCR signaling is reduced.
In summary, two distinct conclusions can be drawn
from these results: first, decreased CD45 expression
increases TCR signaling responses with respect to prolif-
eration for both CD4+ and CD8+ CD44lo T cells; and,
second, when direct comparisons are made between
CD45RO-V821S and its CD45RO9 expression-matched
control, it is clear that the 80% reduction in CD45 PTPase
activity in the former compared to the latter renders both430 Immunity 27, 425–437, September 2007 ª2007 Elsevier IncCD4+ and CD8+ T cells much less responsive to CD3
stimulation.
Reduced Antibody Responses in CD45RO-V821S
PTPase-Low Mice, but Normal CD8+ CTL
Responses
To investigate further the impact of expressing only 3% of
normal CD45 PTPase activity in peripheral T cells, we car-
ried out two functional assays. First, wild-type, CD45RO9,
and CD45RO-V821S mice were immunized with the T-
dependent Ag TNP-KLH. Anti-hapten serum IgG1 from in-
dividual mice was determined at 7, 14, and 77 days after
primary immunization and then 7 and 14 days after rechal-
lenge (Figure 5A). The EC50 of anti-hapten IgG produced
by the transgenic mice after the primary immunization
was significantly lower (t test, p < 0.01) than wild-type,
with CD45RO9 producing 30% and CD45RO-V821S
only 15% of wild-type antibody amounts at day 14. By
day 77, the primary response had declined in both the
CD45RO9 and CD45RO-V821S lines to low levels,.
Immunity
CD45 Regulation of TCR ResponsesFigure 4. CD45RO Peripheral T Cells Display Enhanced Proliferation and TCR Signaling
(A–D) Proliferation of purified splenic CD4 T cells (A, B) or purified CD44lo CD8 T cells (C, D) of wild-type, Ptprc +/, Ptprc /, and CD45 transgenic
mice after CD3 stimulation (A, C) or CD3-CD28 ligation (B, D) for 72 hr. For all assays, cells were stimulated with immobilized CD3 mAb at 0 mg/ml
(clear bar), 0.01 mg/ml (black bar), 0.1 mg/ml (gray bar), and 1 mg/ml (black striped bar) with or without coimmobilized CD28 mAb at 5 mg/ml. Data
are mean ± SD of triplicate samples and are representative of at least three independent experiments.
(E) Flow cytometry of phospho-Erk pThr-202pTyr-204 staining in gated splenic CD4+ or CD44lo CD8+ T cells either basally (dark gray histogram) or
after TCR ligation for 3 min (black line) compared with isotype control (light gray histogram). In all cases, data are representative of three independent
experiments.whereas wild-type mice retained higher amounts of IgG.
After rechallenge, CD45RO9 mice generated memory
IgG responses comparable to wild-type, despite a lower
initial primary response, whereas CD45RO-V821S mice
still produced significantly less Ab (p < 0.01) than either
the wild-type or CD45RO9 mice. An 80% reduction in
CD45 PTPase activity therefore leads to an 85%–90%
reduction in the ability of mice to mount T-dependent Ab
responses, suggesting defective T cell help.ImIn contrast, CD8+ CTL responses were found to be
comparable with wild-type in all three lines (Figure 5B).
Comparison of wild-type, CD45RO transgenic, and
CD45RO-V821S allospecific CTL cells showed equivalent
killing of chromium-loaded target cells at a variety of effec-
tor cell ratios, with only Ptprc/ cells unable to produce
an effective CTL response (Figure 5B). So, despite lower
proliferation, CD45RO-V821S CD8+ T cells could still
produce effective CTL responses.munity 27, 425–437, September 2007 ª2007 Elsevier Inc. 431
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CD45 Regulation of TCR ResponsesDifferential Regulation by CD45 of p56lck pTyr-394
and pTyr-505 in Peripheral T Cells
It is known that CD45 has access to p56lck Tyr phosphor-
ylation sites under basal conditions because p56lck Tyr-
505 becomes hyperphosphorylated in the absence of
CD45 (Stone et al., 1997). In the present work, we used
in situ proximity ligation to demonstrate both CD45-CD3
and CD45-CD4 or CD8-p56lck associations in primary
resting CD4 and CD8 T cells, confirming previous obser-
vations (Figure S5). To elucidate the enzymatic conse-
quences of these associations on TCR signaling
responses at different CD45 PTPase activity, we carried
out a detailed examination of the phosphorylation status
of the activatory pTyr-394 and inhibitory pTyr-505 p56lck
Figure 5. T-Dependent Ab Production Is Reduced in
CD45RO-V821S Mice but CTL Responses Are Normal
(A) EC50 of total anti-hapten IgG from wild-type, CD45RO9, and
CD45RO-V821S mice at 7, 14, and 77 days after primary TNP-KLH
immunization and at 7 and 14 days (d91 and d98, respectively) after
rechallenge. Data points represent results from individual mice.
(B) CTL assays of target cell killing, measured by chromium release, of
effector T cells from wild-type (gray diamond), CD45RO9 (gray circle),
CD45RO-V821S (black triangle), and Ptprc/ (black square) at vari-
ous effector-to-target ratios incubated with allogeneic (filled symbols)
or syngeneic (empty symbols) targets. Effector CTL were primed by
culture with allogeneic (BALB/c) target cells for 5 days prior to killing
assay. Data are representative of three independent experiments.432 Immunity 27, 425–437, September 2007 ª2007 Elsevier Incphosphorylation sites, assaying phosphorylation sepa-
rately in CD4 and CD8 T cells by means of flow cytometry.
Interestingly, wild-type cells have very low basal p56lck
phosphorylation, with about 10% of molecules phosphor-
ylated at each tyrosine (Figure S6). Figure 6A illustrates
dose-response curves, and Figures 6B and 6C are exam-
ples of primary flow cytometric data, in which the in-
creases relative to wild-type in either basal pTyr-505 or
pTyr-394 were assessed in relation to CD45 expression
in CD4+ and CD8+ T cells. Increased basal phosphoryla-
tion in Ptprc/ cells was greater for the pTyr-505 residue
than for the pTyr-394 residue, in the range of 5- to 10-fold
and 3- to 5-fold, respectively, with greater increases
apparent in CD8 than in CD4 cells. A precipitous drop in
pTyr-505 from 5- to 10-fold increase over wild-type to
3- to 4-fold was noted over the range 0%–10% CD45
expression (Figure 6A), a reduction clearly detectable
even when CD45 PTPase activity was only 3% of wild-
type, as in CD45RO-V821S cells (data not shown),
followed by a much gentler decline to 100% of wild-type
amount in both CD4 and CD8 cells. In contrast, the
dephosphorylation of pTyr-394 was less marked over
the 0%–10% CD45 expression range, and whereas
CD45 expression at 30% of wild-type, as in the
CD45RO9 mice, caused a striking 80% reduction in
pTyr-505 compared to Ptprc/, only a 40% reduction in
pTyr-394 was noted. p56lck pTyr-394 remained elevated
over the intermediate CD45 expression range at which T
cells display hyperactivity.
Taken together, these results show that a very lowCD45
expression dephosphorylates sufficient pTyr-505 tomain-
tain p56lck functionality for TCR signal transduction,
whereas much higher amounts of CD45 are necessary
to suppress the pTyr-394 site that is critical for p56lck
activity. Elucidating the differential effects of CD45 at
these two sites provides the key to understanding how
CD45 regulates TCR signaling responses.
DISCUSSION
We have reconstituted Ptprc/ mice with five different
fixed amounts of CD45RO and two mutants of CD45R0,
and we have shown that T cell membrane CD45 PTPase
activity increased in parallel with CD45 expression.
Comparison of the transgenic lines showed that CD45
acted as a rheostat to modulate the sensitivity of cells to
TCR signals and differentially regulate two critical p56lck
kinase phosphorylation sites. Thus, in CD45 null mice,
TCR signaling is very weakly transduced, resulting in
nonresponsive peripheral T cells. However, the incorpora-
tion of only 3% of wild-type CD45 PTPase, as in the
CD45RO-V821Smice, can restore peripheral T cell signal-
ing and function, albeit at a reduced level compared to
wild-type. As the CD45 PTPase activity titrates upwards,
TCR signaling responses increase until they are clearly
higher than wild-type in the CD45RO expression range
10%–60%, typically generating bell-shaped responses
with respect to CD45 expression. The sensitivity of
thymocytes to TCR signals also conform to the same.
Immunity
CD45 Regulation of TCR ResponsesFigure 6. Changes in CD45 Expression and PTPase Activity Cause Differential Changes in p56lck pTyr-394 and pTyr-505 Phosphor-
ylation in Peripheral T Cells
(A) Peripheral CD45 expression and phosphorylation of p56lck pTyr-505 (solid line) and pTyr-394 (dashed line) from CD4+ and CD8+ peripheral T cells.
CD45 expression is presented as percent of wild-type and phosphorylation of p56lck presented as n-fold increase compared to wild-type. Data show
mean ± SEM of a minimum of three individual mice per line.
(B and C) Flow cytometry of p56lck pTyr-505 and pTyr-394 staining (unfilled histogram) in gated splenic T cells compared with wild-type (gray histo-
gram) and isotype control (dark gray histogram). Numbers indicate the n-fold increase in phosphorylation compared with wild-type. Data are repre-
sentative of three independent experiments. Note that no differences in p56lck pTyr-505 and pTyr-394 levels were noted between CD8+ CD44hi and
CD44lo populations, so these cells were pooled for the purposes of the data shown. Insufficient CD8+ Ptprc/ cells were available to generate histo-
grams for this subset in the series shown in (C) (cf. Table S1), but prolonged data collection in further experiments enabled pTyr-505 and pTyr-394
values to be generated for this subset for (A).general pattern, although the fall in responsiveness
over the range 0%–10% CD45 PTPase activity appears
to be even sharper than for peripheral T cells, withImthymocytes in the 10%–14% CD45 expression range dis-
playing reduced TCR-induced signals as compared to
wild-type.munity 27, 425–437, September 2007 ª2007 Elsevier Inc. 433
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signaling as CD45 expression increases from 40% to
100% (of wild-type) is based on the possibility that CD45
homodimerization, which is likely to increase as CD45 ex-
pression increases (Dornan et al., 2002), causes inhibition
of CD45PTPase activity (Majeti et al., 1998). However, two
observations in particular make this explanation unlikely.
First, both thymic and peripheral T cell membrane CD45
PTPase activity increasedwith CD45 expression in a linear
fashion, whereas PTPase inhibition at higher concentra-
tions would predict a different result. Second, if PTPase
activity had been inhibited at the highest CD45RO con-
centrations, then our results suggest that TCR signaling
responses would have increased, not decreased, as we
in fact observed.
Our experiments focused on anti-CD3 ± anti-CD28
stimulation of T cells, which did not result inmajor changes
in the phosphorylation status of Lck (data not shown).
Thus, the effect of CD45 expression on signaling sensitiv-
ity in our experiments is likely to arise from the changes in
basal state Lck phosphorylation observed, consistent with
the associations between CD45, CD3, and CD4/8
whereby CD45 PTPase is brought into proximity with its
Lck substrate. Interestingly, in preliminary experiments,
CD4-coligation very effectively costimulated wild-type
CD4+ T cell proliferation, whereas anti-CD3 alone was suf-
ficient to drive maximal proliferation in CD45RO3 cells
(data not shown). Therefore, it is likely that the interaction
of CD45 with multiple, different pools of intracellular p56lck
are relevant for full activation of TCR-coreceptor signaling
pathways. It is important to note that previous reports
have indicated that crosslinking of TCR-CD4 initiates 4-
fold greater p56lck kinase activity and increased tyrosine
phosphorylation of intracellular substrates compared
with TCR-CD8 crosslinking (Ravichandran and Burakoff,
1994). Furthermore, it has been reported that 10-fold
more p56lck binds to CD4 compared to the CD8 corecep-
tor (Maroun and Julius, 1994) and that this interaction is
18-fold stronger (Campbell et al., 1995), a fact likely to af-
fect the dynamics of the interaction between CD45 and its
kinase substrate. These observations may, in part, explain
the different CD45 expression required for maximal CD4+
versus CD8+ T cell function described in the present work.
These reports are also relevant to the bias of thymocytes
expressing intermediate amounts of CD45 to develop
along the CD4 rather than CD8 lineage, an observation
consistent with previous results showing that thymocytes
are exquisitely sensitive to changes in p56lck activity dur-
ing CD4 and CD8 lineage commitment (Sharp and He-
drick, 1999; Sohn et al., 2001). The p56lck kinase has
been shown to play a direct role in activating the MAP
kinase pathway (Denny et al., 1999; Lin and Abraham,
1997), one of the main downstream signaling pathways
implicated in thymic differentiation (Sebzda et al., 1999),
with a clear correlation between Ras-MAPK pathway acti-
vation and CD4 lineage commitment, consistent with the
observed hyperactivity of this pathway.
Our analysis of p56lck Tyr phosphorylation sites pro-
vides a molecular explanation for the proposed rheostat434 Immunity 27, 425–437, September 2007 ª2007 Elsevier Incfunction of CD45. Although phosphorylation at Tyr-505
and Tyr-394 is known to exert negative and positive ac-
tions, respectively, on p56lck function, these effects are
not equivalent. Phosphorylation at Tyr-505 causes an in-
tramolecular association with the p56lck SH2 domain,
thereby perturbing the interaction(s) of this domain with
potentially important targets in the TCR signaling com-
plex, but exerting relatively little effect on p56lck kinase ac-
tivity (Chong et al., 2005; Pelosi et al., 1999; Sicheri and
Kuriyan, 1997). In contrast, phosphorylation at Tyr-394
has a major effect on p56lck kinase activity (Doro et al.,
1996). Our results showed that in mature T cells, interme-
diate amounts of CD45 PTPase (10%–60% of wild-type)
were highly effective at dephosphorylating pTyr-505, but
relatively less effective in this range at dephosphorylating
pTyr-394. Therefore, the 1.4- to 2.1-fold increases in pTyr-
394 levels in CD4 cells over this CD45 expression range
appeared to dominate p56lck function, causing TCR sig-
naling responses greater than wild-type. In contrast,
CD45 at low expression was relatively less efficient at de-
phosphorylating pTyr-505, especially in CD8+ cells, so the
hyperactivatory influence of increased pTyr-394 in this
context may be counteracted by the inhibitory conse-
quences of high pTyr-505. But in peripheral T cells, at
least, the dominant effect on p56lck function appears to
be the increased pTyr-394 observed over the 10%–60%
CD45 expression range. We therefore propose that the
main reason why T cells express so much CD45 is to en-
sure effective pTyr-394 dephosphorylation under basal
conditions, thereby damping T cell activation and prevent-
ing autoimmunity. However, a low amount of CD45 is
absolutely required to effectively dephosphorylate pTyr-
505 and prevent p56lck dysfunction, as is apparent in
Ptprc/ mice.
After TCR stimulation, additional phosphatases are
likely to be involved in regulation of p56lck function. In-
deed, recent data from Germain and colleagues indicate
a critical role for SHP-1 in inhibition of p56lck function
and TCR signaling in response to partial agonist or antag-
onist peptides (Stefanova et al., 2003). Our results are per-
tinent to the role of CD45 in the immune synapse and in the
recently described microclusters that sustain TCR signal-
ing (Campi et al., 2005; Yokosuka et al., 2005). Whereas
exclusion of CD45 from microclusters has been associ-
ated with prolongation of TCR signaling, CD45 was pres-
ent in cSMACs in which signaling stops (Varma et al.,
2006). CD45-primed p56lck may diffuse into clusters
from surrounding CD45-rich domains (Douglass and
Vale, 2005). In the context of these models, our results
suggest that very small amounts of CD45 would be suffi-
cient to prime p56lck for cluster signaling, whereas much
higher amounts are needed to stop signaling, conditions
that appear to be generally consistent with the reported
imaging data.
Our results showed that a higher proportion of CD8+ T
cells from CD45RO transgenic mice express high
amounts of CD44, indicative of an activated or ‘‘memory’’
phenotype. Given that numbers of thymic CD8+ SP cells
were similar in all lines of mice with the exception of the.
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result of lymphopenia-induced proliferation and gain of
memory-like attributes. We have assessed the phenotype
of thymic CD8+ SP cells in CD45RO mice: these are ma-
ture (TCRhi) and express low amounts of CD44, indicating
that the acquisition of a memory phenotype occurs when
these cells leave the thymus (data not shown). The under-
lying reason for this phenotype is not yet fully understood
and requires further investigation. In contrast, CD44
expression on CD45RO transgenic CD4+ T cells was not
altered.
When in vivo antibody responses to the T-dependent
antigen TNP-KLH were measured, the intermediate line
RO9 (29.8% wild-type CD45 level) was found to make
a lower primary IgG1 than the wild-type strain despite be-
ing mildly hyper-responsive to anti-CD3 (± anti-CD28)
in vitro. This may reflect the greater influence of costimu-
lation in wild-type cells in the in vivo situation as well as
possible impairment of B cell function and survival in
the RO9 mice (Huntington et al., 2006); the secondary
response of RO9 was not different to wild-type. By con-
trast, the ability of effector allospecific CTL from the
CD45 transgenic lines to kill fully allogeneic targets was
not different even for the V821S line (3% activity). The sen-
sitivity of CTL is believed to be very high with less than 10
complexes required to elicit effector function for CD45
wild-type cells (Purbhoo et al., 2004); given the relatively
high density of allo-MHC on targets, such considerations
may well permit effective activation even with inefficient
signal transduction capabilities.
Comparison of CD45RO-V821S with expression-
matched CD45RO9 transgenic mice enabled direct inves-
tigation of the consequences for primary T cell activation
of reducing the CD45 PTPase activity by 80% in mice
with comparable amounts of CD45 protein. This reduction
was associated with a major reduction in proliferation,
primary and secondary responses to antigen, and TCR-
mediated signaling, associated with a 2-fold increase in
pTyr-505 levels. Yet assessment of CD45 as a potential
pharmaceutical target to induce immunosuppression
must consider the wider picture (Alexander, 2005). Unless
90% or more of CD45 PTPase activity is inhibited, our
results suggest that partial inhibition of CD45 would run
a serious risk of rendering T cells hyperactive, a consider-
able challenge to selective pharmaceutical intervention.
EXPERIMENTAL PROCEDURES
Mice
All mice were bred and maintained in specific pathogen-free condi-
tions in the animal facilities at The Babraham Institute (Cambridge,
UK), and all procedures were conducted under United Kingdom
Home Office guidelines. Point mutations Cys817-Ser (C817S) and
Val821-Ser (V821S) were introduced into cDNA encoding the
CD45RO isoform by the QuikChange Site-Directed Mutagenesis Kit
(Stratagene). The cDNA was inserted into the NotI site of the HS321/
45 vav-hCD4 plasmid (Ogilvy et al., 1999), and transgenics were cre-
ated as previously described (Ogilvy et al., 2003). Transgenic pups
were identified by PCR on DNA extracted from tail biopsies with
primers specific to the transgenic SV40 poly sequence (Ogilvy et al.,
1999). Transgenic founder mice were mated to previously describedImmB6.129-Ptprctm1holm CD45 exon 9/mice (Byth et al., 1996) to gener-
ate transgene-bearing animals that lacked expression of all endoge-
nous CD45 isoforms. Mice were backcrossed to the Ptprc/,
C57BL/6 background for aminimumof 7 generations.Mice expressing
the vav-CD45RO transgene at a variety of levels have been previous
described (Ogilvy et al., 2003) and Ptprc/, Ptprc+/, and wild-type
C57BL/6 were used as control mice. Experiments used age- and
sex-matched mice.
T Cell Stimulation, Flow Cytometry, and Antibodies
Single-cell suspensions were stained for 30 min with antibodies
obtained from BD PharMingen, unless otherwise stated, to the follow-
ing cell-surface markers: CD3 (Clone 145-2C11; in-house hybridoma),
CD4 (Clone CT-CD4, Caltag; Clone YTA3.1, in-house hybridoma), CD8
(Clone YTS169, in-house hybridoma), CD25 (Clone PC61), CD44
(Clone IM7), CD45 (Clone 30-F11), CD62L (Clone MEL-14; Caltag),
and CD69 (Clone H1-2F3) in flow cytometry buffer (PBS with 0.5%
FCS and 0.05% sodium azide). Cells were washed and analyzed on
a FACSCalibur flow cytometer (BD Biosciences) and data were ana-
lyzed with FlowJo FACS Analysis software (Tree Star). For intracellular
staining, T cells were resuspended in RPMImedium and prewarmed to
37C for 30min at a concentration of 107/ml. T cells were stimulated by
the addition of anti-CD3 (Clone 2C11) at a concentration of 2 mg/ml, 10
mg/ml, or 50 mg/ml for 1, 3, or 10min. Stimulation was stopped by fixing
with 2% formaldehyde for 10min at 37Cprior to permeabilization with
ice-cold 90% methanol for a minimum 30 min. Cells were stained with
signaling protein antibodies (Cell Signaling Technology): anti-phos-
pho-p44/42 Map Kinase (Thr-202/204), anti-phospho-AKT (Ser-473),
anti-phospho-Lck (Tyr-505), and anti-phospho-Src family (Tyr-416)
and detected with a Cy-5-labeled minimal crossreactive AffiniPure
Donkey anti-rabbit IgG (Jackson ImmunoResearch Labs).
T Cell Purification
Spleen and lymph node cells were prepared from 8- to 10-week-old
mice and T cells purified with the Spinsep mouse T cell enrichment
kit (Stem Cell Technologies), with the addition of anti-CD19 (Clone
1D3; PharMingen) to remove transgenic B cells that did not express
B220. For purification of T cell subsets, further addition of anti-CD8
(Clone 53.8.7; PharMingen) for CD4 T cell enrichment, or anti-CD4
(Clone GK1.5; PharMingen) for CD8 T cell enrichment, was used.
CD8 T cells were further purified into CD44lo and CD44hi populations
by the addition of FITC-conjugated anti-CD44 (Clone IM7; PharMin-
gen) and sorted with the FACSAria cell sorter (BD Biosciences). Final
cell suspensions were greater than 90% CD3+, 90% CD4+, or 98%
CD44lo CD8+, as determined by flow cytometry.
Membrane PTPase Activity
Membrane fractions from thymocyte or purified CD4 or CD8 peripheral
T cell suspensions were prepared by sonication and ultracentrifuga-
tion. Cells were suspended in 20 mM HEPES (pH 7.4), 5 mM EDTA,
1 mM MgCl, 10 mM 2-mercaptoethanol, and were disrupted by soni-
cation. Nuclei were pelleted by centrifugation, and the remaining
homogenate was resolved into cytoplasmic (soluble) and membra-
nous (particulate) components by ultracentrifugation (95,000 3 g for
90 min at 4C). Membrane pellets were resuspended in 20 mMHEPES
with 10 mM 2-mercaptoethanol and analyzed with the PTP Assay Kit 1
(Upstate Biotechnology) according to the manufacturer’s instructions.
PTPase activity was standardized between samples to protein con-
centration as measured with the BioRad Protein Assay (BioRad).
Immunization
Samples of preimmune sera were taken 7 days before the initial
immunization. Groups of mice were immunized i.p. with 100 mg trinitro-
phenyl-keyhole limpet hemocyanin (TNP-KLH; Biosearch Technolo-
gies) emulsified in alum (Alu-Gel-S; Serva Electrophoresis). Samples
of blood from tail veins were taken on days 7, 14, and 77 postimmuni-
zation. For secondary responses, mice received a further 100 mg of
TNP-KLH/alum on day 84, with tail bleeds taken on days 91 and 98.unity 27, 425–437, September 2007 ª2007 Elsevier Inc. 435
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coated with 5 mg/ml TNP-OVA (Biosearch Technologies) overnight.
Plates were blocked by addition of PBS/1% BSA for 1 hr. Serial
dilutions of sera were added and specific Ab isotype detected with
Clonotyping System-HRP (Southern Biotechnology Associates).
EC50 values for anti-TNP titers were calculated by nonlinear regression
analysis with Prism software (GraphPad software).
CTL Assay
Cells were obtained from disaggregated spleens of transgenic or
control C57BL/6 mice (responder) and from Balb/c mice (stimulator).
Allogeneic CTL were stimulated by culture in Falcon 3013 flasks con-
taining 107 irradiated (30Gy) stimulator cells and an equal number of
responder cells, except where the individual transgenic animal had
significantly (<66%) fewer CD8+ T cells, in which case the number of
responder cells was adjusted to give a similar ratio of CD8 responders
to stimulators for all cultures. Cells were cultured in RPMI 1640 supple-
mented with 10% FCS, 53 105 M 2-mercaptoethanol, and penicillin,
streptomycin for 5 days. Effector cells were recovered from cultures
and pooled, and viable counts were determined. Cytotoxicity assays
were performed by a 6 hr Cr51 release method in Falcon 3072 96-
well plates. M12C3 cells (H-2d) and control RMA cells (H-2b) were
used as targets (104/well) and effectors titrated as shown.
Proliferation Assay
Proliferation was assessed by [3H]-thymidine incorporation. 1 3 105
enriched CD4 and CD44lo CD8 T cells were stimulated for 72 hr
(proliferation) with plate-bound anti-CD3 (Clone 2C11, 0.01–1 mg;
PharMingen) with or without anti-CD28 (Clone 37.52, 5 mg; PharMin-
gen). Cells were pulsed for the final 16 hr of culture with 1 mCi [3H]-thy-
midine (Amersham) per well, and incorporated label was quantified by
scintillation counting.
Statistical Methods
An unpaired two-tailed Student’s t test was used to determine signifi-
cant differences to wild-type, with p values less than 0.01 considered
significant.
Supplemental Data
Six figures, one table, and Experimental Procedures are available at
http://www.immunity.com/cgi/content/full/27/3/425/DC1/.
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